Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Call Transcript

Kamal Hamed: Okay, no, thank you. Thank you, Louise. So, I mean, the recent news is certainly unfortunate for patients, because patients need newer combination agents that have better tolerability and effectiveness. But having said that, we are targeting a different patient population, than the patient population that’s targeted, by the other ongoing trial, with oral therapy. So, we aim to develop 720, as Sath said, as a first-line therapy for treatment naive patients or treatment experience patients with non-refractive disease. And as we know, this patient segment comprises the majority of patients, about 75% of the patient population. And I should note that 720 demonstrated, potent activity against MAC, low propensity for selection of resistance in an in vitro resistance development study.

We’ve also proceeded with a Phase 2a study, which is the ongoing clinical trial at this time, with the aim to assess the biological effect of SPR720, before we combine it with standard care agents and later stage, Phase 2b/3 program.

Louise Chen: Okay. And anything on the market opportunity for 206?

Esther Rajavelu: Yes, maybe I’ll take that, Louise. I think 206 presents an interesting opportunity for patients, because there is a high degree of unmet need in that patient population. However, we’ve always commented that we would continue developing that program contingent on non-dilutive sources of funding. As you know, we have a – partnership with Pfizer for European markets and with Everest for China. And we also collaborate with government agencies to obtain funding. So we’re looking at, any and all of those sources, for continued funding for that program.

Louise Chen: Thank you.

Operator: Thank you. There are no further questions at this time. I would like to hand the call back to Mr. Shukla for any closing comments.

Sath Shukla: Well, I’d just like to thank everyone for dialing in today and have a wonderful day.

Operator: This concludes today’s conference. You may disconnect your lines at this time. Thank you for your participation.